Stockscreener 앱 받기
10.37
2.78%
-0.35
전일 마감가:
$10.72
열려 있는:
$10.6
하루 거래량:
45,693
Relative Volume:
0.20
시가총액:
$363.65M
수익:
$51.00M
순이익/손실:
$-8.73M
주가수익비율:
-35.01
EPS:
-0.2962
순현금흐름:
$-7.75M
1주 성능:
-16.29%
1개월 성능:
-11.08%
6개월 성능:
+38.59%
1년 성능:
+20.21%
1일 변동 폭
$10.29
$10.60
1주일 범위
$10.34
$12.45
52주 변동 폭
$5.65
$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
명칭
Fennec Pharmaceuticals Inc
전화
(919) 636-4530
주소
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
10.37 | 384.34M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
511.92 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.88 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.60 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.89 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
201.91 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 개시 | B. Riley Securities | Buy |
| 2026-01-09 | 개시 | Piper Sandler | Overweight |
| 2022-11-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | 개시 | CapitalOne | Overweight |
| 2022-08-08 | 재개 | Craig Hallum | Buy |
| 2020-06-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-11 | 개시 | Goldman | Buy |
모두보기
Fennec Pharmaceuticals Inc 주식(FENC)의 최신 뉴스
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
Fennec Pharmaceuticals Stock Price Forecast. Should You Buy FRX.TO? - StockInvest.us
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Insider Rosty Raykov Reports Share Vesting and Sale - Kalkine Media
Former Fennec (NASDAQ: FENC) director lines up $121K stock sale - Stock Titan
Former Fennec Pharma (NASDAQ: FENC) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Fennec CCO receives 168 shares at zero cost - Stock Titan
Fennec Pharma CEO gains 1,159-share award - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 12,000 shares - Stock Titan
Fennec (NASDAQ: FENC) CMO sells 12,000 vested shares in an August 31 trade not tied to a preset Rule 10b5-1 plan. - Stock Titan
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - webull.com
Fennec Pharma (NASDAQ: FENC) CFO sells 75K shares in plan trade - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 75,000 shares - Stock Titan
Fennec Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:FENC - TradingView
Fennec (FENC) Results Review: Reported EPS Tops Expectations in the Latest Reading; Share Response: The Share Price Sheds 4.63% at the CloseEPS Estimate Trend - vinanet.vn
Fennec (FENC) Results Check: Profit Per Share Clears Its Benchmark on the Day; Investor Response - vinanet.vn
Fennec (FENC) Technical Check: Adds 0.51% to Close at $11.89 at the Close; Current Setup: the Supplied Trading Band Runs From $11.30 to $12.48Throwback Trade - vinanet.vn
Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals - hrtoday.in
(FENC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Maxim Group - The Globe and Mail
Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake - Stock Titan
Results: Fennec Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
Fennec Pharmaceuticals Announces Q2 2026 Net Income and Revenue Growth - Kalkine Media
Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question - webull.com
Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush - The Globe and Mail
B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC) - MarketBeat
Wedbush Boosts Adherex Technologies (NASDAQ:FENC) Price Target to $16.00 - MarketBeat
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade) - Seeking Alpha
Why Fennec Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating - marketscreener.com
Fennec Pharmaceuticals Inc FRX Earnings Beat Estimates by 248.5% - Wealth Awesome
Adherex Technologies Q2 2026 Earnings Call Transcript - MarketBeat
Fennec Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $16.17, Implies 48% Upside - TradingView
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... - Yahoo Finance
Fennec Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adherex Technologies Q2 Earnings Call Highlights - newsbreak.com
Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat - marketscreener.com
Adherex Technologies (NASDAQ:FENC) Announces Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates - Yahoo Finance
Transcript : Fennec Pharmaceuticals Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Fennec Pharmaceuticals Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Fennec Pharmaceuticals posts second quarter results and issues business update - tradersunion.com
Fennec Pharmaceuticals surges 8% on Q2 earnings, revenue beat By Investing.com - Investing.com Nigeria
Fennec Pharmaceuticals surges 8% on Q2 earnings, revenue beat - Investing.com
FENNEC PHARMACEUTICALS ($FENC) Releases Q2 2026 Earnings - Quiver Quantitative
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Fennec Pharmaceuticals Inc (FENC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fennec Pharmaceuticals Inc 주식 (FENC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Former Director |
Sep 01 '26 |
Sale |
12.11 |
10,000 |
121,100 |
124,411 |
| Sayad Pierre Sargis | Chief Medical Officer |
Aug 31 '26 |
Sale |
12.18 |
12,000 |
146,160 |
9,519 |
1.26%
자본화:
|
볼륨(24시간):